Tier 2 — strong

Does Quercetin Improve Cardiovascular Risk factors and Inflammatory Biomarkers in Women with Type 2 Diabetes: A Double-blind Randomized Controlled Clinical Trial

Maryam Zahedi, Reza Ghiasvand, Awat Feizi, Gholamreza Asgari, Leila Darvish
International journal of preventive medicine 2013 4(7):777

Bibliography

PubMed
PMID 24049596
PubMed Central
PMC3775217
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: None declared.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample72 women with type 2 diabetes
InterventionQuercetin 500 mg/day or placebo
Duration10 weeks
EndpointsBlood pressure; Lipid measurements; Inflammatory measures

What the study showed, in plain terms

Published in 2013, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled trial. Sample/model: 72 women with type 2 diabetes. The exposure or intervention was Quercetin 500 mg/day or placebo. Follow-up or treatment period: 10 weeks.

Systolic pressure fell more with quercetin than placebo. Between-group differences in diastolic pressure, lipids, and measured inflammatory markers were not significant.

Within-group cytokine changes should not be interpreted as placebo-controlled efficacy. The study measured risk markers rather than diabetes complications or cardiovascular events.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Systolic pressure fell more with quercetin than placebo.
  • Between-group differences in diastolic pressure, lipids, and measured inflammatory markers were not significant.
  • The recorded outcome domains were Blood pressure; Lipid measurements; Inflammatory measures.
  • The result applies to the tested exposure: Quercetin 500 mg/day or placebo; 10 weeks.

What this study can and cannot tell us

  • Within-group cytokine changes should not be interpreted as placebo-controlled efficacy. The study measured risk markers rather than diabetes complications or cardiovascular events.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology